The Relationship of Cyclooxygenase -2 (COX-2) Expression with Clinical Presentation, Staging, and Degree of Differentiation in Colorectal Cancer

Authors

  • Ibrahim Labeda Division of Digestive Surgery, Department of Surgery, Faculty of Medicine, Universitas Hasanuddin
  • Julianus A Uwuratuw Division of Digestive Surgery, Department of Surgery, Faculty of Medicine, Universitas Hasanuddin
  • Berti Nelwan Department of Pathology Anatomy, Faculty of Medicine, Universitas Hasanuddin
  • Prihantono Prihantono Department of Surgery, Faculty of Medicine, Universitas Hasanuddin

Keywords:

Colorectal Cancer, COX-2, Immunohistochemistry, Expression, Differentiation, Stage.

Abstract

Colorectal cancer (CRC) is a common malignancy worldwide. Although the recent development of adjuvant treatment has developed rapidly, it has only slightly Increased the survival rate of CRC Patients in an advanced stage. The prognosis of CRC patient strongly influenced by Several factors, such as tumor stage, clinical manifestations, histopathology and molecular oncogenicity of the tumor. COX-2 is an enzyme that plays a role in converting arachidonic acid into prostaglandins. The end product of COX-2 contributes to various biological factors in triggering tumor growth. The purpose of this research is to know the relationship of COX-2 expression with the clinical presentation such as patient age, location, and size of the tumor and histopathology in CRC patients.

References

[ 1 ] Raskov H, Pommergaard HC, Burcharth J, Rosenberg J. Colorectal Carcinogenesis update, and perspectives. World J Gastroenterol. 2014; 20 (48): 18151-4.

[ 2 ] Colorectal Cancer patient data from 2005 - 2010. MAKASSAR: Digestive Surgery Medical Faculty of Hasanuddin University, 2011.

[ 3 ] Bullard KM, Rothenberger DA. Colon, rectum, and anus. In: Brunicardi FC, editor. Schwartz'sPrinciples of Surgery. New York: The McGraw-Hill Companies; 2015. p. 1175-230.

[ 4 ] Today DM, Leung AM, Lee JH, Sim MS, Vuong B, Chiu CG, et al. 7TH-Edition AJCC Staging Criteria for Colon Cancer: Do the Complex Modifications prognostic Improve Assessment? J Am Coll Surg. 2013; 217 (2): 181-90.

[ 5 ] Gries LA, Eisner MP, Kosary CL. SEER Cancer Statistics review 1973 - 1995. The 1998 Bethesda Md.

[ 6 ] Garcia-Aguilar J. Perspectives on rectal AND ANAL CANCER. In: Zinner MJ, Ashley SW, editors. Mainggot's Abdominal Operations. 12 the ed. New York: Mc Graw Hill Medical; 2012. p. 833-68.

[ 7 ] Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer and Metastasis Review. 2004; 23: 63-75.

[ 8 ] Lusikooy RE, Sampetoding S. Characteristics of colorectal cancer in Indonesia; Epidemiologic studies based Hospital based data is the first National Seminar Makassar Colorectal Cancer (MCC) in 2011 at 14, the Education Center of Surgery in Indonesia. Surgery magazine Makassar. 2013; 2 (2013): 7 -11.

[ 9 ] Miladi-Abdennadher I, Abdelmaksoud-Dammak R, Ayed-Guerfali DB, Ayadi L, Khabir A, Amouri A, et al. Expression of COX-2 and E-cadherin in Tunisian Patients with colorectal adenocarcinoma. Acta Histochemica. 2012; 114: 577-81.

[ 10 ] Masunaga R, Kohno H, DK Dhar, Ohno S, Shibakita M, Kinugasa S, et al. Cyclooxygenase-2 Expression Correlates with Tumor neovascularization and Prognosis in Human Colorectal Carcinoma Patients. Clinical Cancer Research. 2000 6 4064 - 88.

[ 11 ] Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T, et al. Cyclooxygenase-2 overexpression correlates with tumor recurrence, especially hematogenous metastasis, of colorectal cancer. British Journal of Cancer. 2000; 3 (83): 324-8.

[ 12 ] Nasir A, Lopez A, Boulware D, Malafa M, Coppola D. Correlation between COX-2 and APC Expression in Left Versus Right-sided Human Colon Cancer. Anticancer RESEARCH. 2011; 31: 2191-6.

[ 13 ] Dimberg J, Samuelsson A, Hugander A, S

[ 14 ] Divvela AKC, Challa SR, Tagaram IK. The pathogenic role of cyclooxygenase-2 in cancer. Journal of Health Science. 2010; 56 (5): 502-16.

[ 15 ] Peng L, Zhou Y, Wang Y, Mou H, Zhao Q. prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: a meta-analysis of the literature PLoS One. 2013; 8.

[ 16 ] Al-Maghrabi J, Buhmeida A, E Emam, Syrjanen K, Sibiany A, Al-Qahtani M, et al. Cyclooxygenase-2 expression as a predictor of outcome in colorectal carcinoma. World J Gastroenterol. 2012; 18: 1793-9.

[ 17 ] Wensum D, Masliah J, Trugnan G, Flojou JF. Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch. 2004; 445: 327-33.

[ 18 ] Wu QB, Sun GP. Expression of COX-2 and HER-2 in colorectal cancer and their correlation. World J Gastroenterol 2015 21 (20): 6206-14.

[ 19 ] Khuri FR, Wu H, JJ Lee, Kemp BL, Lotan R, Lippman SM, et al. Cyclooxygenase-2 overexpression Is a Marker of Poor Prognosis in Stage I Non-Small Cell Lung Cancer. Clinical Cancer Research. 2001; 7: 861- 7.

[ 20 ] Sheehan KM, O'Connell M, O'Grady A, R Conroy, Ronan MB, Leader M, et al. The relationship between cyclooxygenase-2 expression and characteristics of malignant transformation in human colorectal adenomas. European Journal of Gastroenterology & Hepatology. 2004; 16 (6): 619-25.

[ 21 ] RB Nogueira, ARC Pires, Soares TMS, SRS Rodrigues, MAM Campos, Toloi GC, et al. Immunoexpression of the COX-2, p53, and caspase-3 proteins in colorectal adenomas and non-neoplastic mucosa. Einstein. 2013; 11 (4): 456-61.

Downloads

Published

2017-07-29

How to Cite

Labeda, I., A Uwuratuw, J., Nelwan, B., & Prihantono, P. (2017). The Relationship of Cyclooxygenase -2 (COX-2) Expression with Clinical Presentation, Staging, and Degree of Differentiation in Colorectal Cancer. International Journal of Sciences: Basic and Applied Research (IJSBAR), 35(1), 64–75. Retrieved from https://www.gssrr.org/index.php/JournalOfBasicAndApplied/article/view/7734

Issue

Vol. 35 No. 1 (2017)

Section

Articles

License

Authors who submit papers with this journal agree to the following terms.